• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Changes in malondialdehyde levels in bronchoalveolar fluid and serum by the treatment of asthma with inhaled steroid and beta2-agonist.

作者信息

Ozaras R, Tahan V, Turkmen S, Talay F, Besirli K, Aydin S, Uzun H, Cetinkaya A

机构信息

Internal Medicine, Istanbul University, Turkey.

出版信息

Respirology. 2000 Sep;5(3):289-92. doi: 10.1046/j.1440-1843.2000.00260.x.

DOI:10.1046/j.1440-1843.2000.00260.x
PMID:11022993
Abstract

OBJECTIVE

Oxidative stress plays an important role in the pathogenesis of asthma. Recent data suggest that clinical indices of the patients with asthma may not correlate with the underlying inflammatory process. We aimed to measure the level of malondialdehyde (MDA), which is a marker of lipid peroxidation, a free radical-mediated process, before and after a well-accepted treatment of asthma.

METHODOLOGY

Nine non-smoking females and five non-smoking males with mild-moderate asthma were included. Twenty-four age- and sex-matched, non-smoking healthy people (17 females and seven males, mean age 32.1 years, range 20-59) were included for control. After initial evaluation, spirometry, bronchoscopy with bronchoalveolar lavage (BAL), and blood sample were maintained. The patients were treated with twice-daily salmeterol inhaler (100 microg/d) and fluticasone propionate inhaler (500 microg/d). One month later the investigations were repeated. Serum MDA levels before treatment were compared with both the levels after treatment and levels of controls. Malondialdehyde levels of BAL were compared before and after treatment.

RESULTS

Serum MDA level of the patient before treatment was 6.7+/-0.8 nmol/mL, significantly higher than that of healthy controls; 3.8+/-0.4, P < 0.001. One month after the treatment, serum MDA level decreased to 5.3+/-0.7 nmol/mL (P < 0.001). However, this level is still significantly higher than healthy controls (P < 0.0001). Forced expiratory volume in 1 s level of the patients increased from 2.43+/-0.79 L to 3.50+/-1.21 L after the treatment (P < 0.001).

CONCLUSION

Although treatment with beta2-agonist and corticosteroid inhalers for the duration of 1 month reduced lipid peroxidation significantly, it was still at a level significantly higher than healthy controls. The treatment may need a longer duration to improve lipid peroxidation or an alternative regimen which is more effective in controlling inflammation may be warranted.

摘要

相似文献

1
Changes in malondialdehyde levels in bronchoalveolar fluid and serum by the treatment of asthma with inhaled steroid and beta2-agonist.
Respirology. 2000 Sep;5(3):289-92. doi: 10.1046/j.1440-1843.2000.00260.x.
2
Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma.吸入沙美特罗和氟替卡松:一项比较哮喘单一疗法与联合疗法的研究。
Ann Allergy Asthma Immunol. 1999 Mar;82(3):257-65. doi: 10.1016/S1081-1206(10)62606-3.
3
Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting beta2-agonists.在使用短效β2受体激动剂控制效果欠佳的患者中,与单独使用沙美特罗或丙酸氟替卡松相比,通过都保装置使用丙酸氟替卡松和沙美特罗。
Ann Allergy Asthma Immunol. 2004 Oct;93(4):351-9. doi: 10.1016/S1081-1206(10)61394-4.
4
Salmeterol/fluticasone propionate (50/500 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma.沙美特罗/丙酸氟替卡松(50/500微克)联合使用的准纳器吸入器(舒利迭)在治疗激素依赖型哮喘方面有效且安全。
Respir Med. 1999 Dec;93(12):876-84. doi: 10.1016/s0954-6111(99)90053-7.
5
Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study.丙酸氟替卡松/沙美特罗通过氢氟烷烃134a定量吸入器每日两次给药在青少年和成年持续性哮喘患者中的疗效和耐受性:一项随机、双盲、安慰剂对照的12周研究。
Clin Ther. 2006 Jan;28(1):73-85. doi: 10.1016/j.clinthera.2006.01.008.
6
Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study.丙酸氟替卡松/昔萘酸沙美特罗氢氟烷计量吸入器在青少年和成年持续性哮喘患者中的耐受性:一项为期52周的开放标签、分层、平行组、多中心研究。
Clin Ther. 2007 Jul;29(7):1390-402. doi: 10.1016/j.clinthera.2007.07.021.
7
Inhaled salmeterol/fluticasone propionate combination: a review of its use in persistent asthma.吸入用沙美特罗/丙酸氟替卡松联合制剂:其在持续性哮喘中应用的综述
Drugs. 2000 Nov;60(5):1207-33. doi: 10.2165/00003495-200060050-00012.
8
Salmeterol and fluticasone propionate (50/250 microg) administered via combination Diskus inhaler: as effective as when given via separate Diskus inhalers.通过联合使用都保吸入器给药的沙美特罗和丙酸氟替卡松(50/250微克):与通过单独的都保吸入器给药时效果相同。
Can Respir J. 1999 Jan-Feb;6(1):45-51. doi: 10.1155/1999/894803.
9
Addition of salmeterol to fluticasone propionate treatment in moderate-to-severe asthma.在中重度哮喘患者中,沙美特罗添加至丙酸氟替卡松治疗方案中。
Respir Med. 2003 May;97(5):555-62. doi: 10.1053/rmed.2003.1483.
10
Effects of salmeterol on mucosal inflammation in asthma: a placebo-controlled study.沙美特罗对哮喘患者黏膜炎症的影响:一项安慰剂对照研究。
Eur Respir J. 2002 Dec;20(6):1378-85. doi: 10.1183/09031936.02.00542001.

引用本文的文献

1
Chemical knockdown of Keap1 and homoPROTAC-ing allergic rhinitis.通过化学方法敲低Keap1以及同型PROTAC治疗过敏性鼻炎
Acta Pharm Sin B. 2025 Aug;15(8):4137-4155. doi: 10.1016/j.apsb.2025.05.025. Epub 2025 May 27.
2
Association between oxidative balance score and asthma course in the American children: A cross-sectional analysis of the NHANES 2011-2018.美国儿童氧化平衡评分与哮喘病程的关联:对2011 - 2018年美国国家健康与营养检查调查(NHANES)的横断面分析。
Medicine (Baltimore). 2025 Apr 25;104(17):e42262. doi: 10.1097/MD.0000000000042262.
3
Photobiomodulation Mitigates PM-Exacerbated Pathologies in a Mouse Model of Allergic Asthma.
光生物调节减轻过敏性哮喘小鼠模型中PM加重的病理状况。
Antioxidants (Basel). 2024 Aug 19;13(8):1003. doi: 10.3390/antiox13081003.
4
Neutralizing Oxidized Phosphatidylcholine Reduces Airway Inflammation and Hyperreactivity in a Murine Model of Allergic Asthma.中和氧化磷脂酰胆碱可减轻变应性哮喘小鼠模型的气道炎症和高反应性。
Biology (Basel). 2024 Aug 17;13(8):627. doi: 10.3390/biology13080627.
5
The Role of Exhaled Breath Condensate in Chronic Inflammatory and Neoplastic Diseases of the Respiratory Tract.呼出气冷凝物在呼吸道慢性炎症和肿瘤性疾病中的作用。
Int J Mol Sci. 2024 Jul 5;25(13):7395. doi: 10.3390/ijms25137395.
6
The correlation between selenium intake and lung function in asthmatic people: a cross-sectional study.哮喘患者硒摄入量与肺功能的相关性:一项横断面研究。
Front Nutr. 2024 May 17;11:1362119. doi: 10.3389/fnut.2024.1362119. eCollection 2024.
7
Malondialdehyde as a Potential Oxidative Stress Marker for Allergy-Oriented Diseases: An Update.丙二醛作为一种潜在的与过敏相关疾病的氧化应激标志物:最新研究进展。
Molecules. 2023 Aug 9;28(16):5979. doi: 10.3390/molecules28165979.
8
Analysis of a Broad Range of Carbonyl Metabolites in Exhaled Breath by UHPLC-MS.利用 UHPLC-MS 分析呼出气体中的多种羰基代谢物。
Anal Chem. 2023 Mar 7;95(9):4344-4352. doi: 10.1021/acs.analchem.2c04604. Epub 2023 Feb 23.
9
Overview of the Mechanisms of Oxidative Stress: Impact in Inflammation of the Airway Diseases.氧化应激机制概述:对气道疾病炎症的影响
Antioxidants (Basel). 2022 Nov 13;11(11):2237. doi: 10.3390/antiox11112237.
10
Oxidative stress in patients with asthma and its relation to uncontrolled asthma.哮喘患者的氧化应激及其与未控制哮喘的关系。
J Clin Lab Anal. 2022 May;36(5):e24345. doi: 10.1002/jcla.24345. Epub 2022 Mar 22.